GS
ALNY icon

GTS Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

GTS Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Buy
1,452
+400
+38% +$121K 0.01% 781
2026
Q1 		$348K Buy
1,052
+527
+100% +$179K 0.01% 1007
2025
Q4 		$209K Buy
+525
New +$232K 0.01% 1260
2025
Q3 		– Sell
-747
Closed -$244K – 1414
2025
Q2 		$244K Buy
+747
New +$207K 0.01% 1017
2025
Q1 		– Sell
-1,163
Closed -$274K – 1225
2024
Q4 		$274K Sell
1,163
-7,040
-86% -$1.85M 0.01% 940
2024
Q3 		$2.26M Buy
8,203
+7,107
+648% +$1.85M ﹤0.01% 1490
2024
Q2 		$266K Buy
+1,096
New +$173K ﹤0.01% 3227
2024
Q1 		– Sell
-1,966
Closed -$328K – 3795
2023
Q4 		$376K Buy
+1,966
New +$335K ﹤0.01% 3019

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GTS Securities's ALNY Position: Q2 2026 in Review

GTS Securities increased its Alnylam Pharmaceuticals (ALNY) stake by 38% in Q2 2026, buying an estimated $121K and bringing the position to 1,452 shares worth $437K. The position accounts for 0.01% of the portfolio, ranked #781.

GTS Securities first reported a position in ALNY in Q4 2023 and has held it in 8 quarters since. The position peaked at $2.26M in Q3 2024. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • GTS Securities held 1,452 shares of Alnylam Pharmaceuticals worth $437K as of Q2 2026.
  • GTS Securities bought 400 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $121K.
  • Alnylam Pharmaceuticals made up 0.01% of GTS Securities's portfolio in Q2 2026, its #781 holding.
  • GTS Securities first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
  • GTS Securities's Alnylam Pharmaceuticals position peaked at $2.26M in Q3 2024.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.